#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hodgkin's disease refractory Hodgkin's disease Hereditary haemorrhagic telangiectasia Thrombotic thrombocytopenic purpura Cutaneous T-cell lymphoma Primary hyperoxaluria Myelodysplastic syndrome with excess blasts Leber's congenital amaurosis Ductal adenocarcinoma of pancreas Oropharyngeal cancer recurrent Glomerulonephritis membranous Progressive multifocal leukoencephalopathy Pulmonary tuberculosis Superficial vein thrombosis Small intestine neuroendocrine tumour More trials…

    Learn about Rare Diseases

    Encephalitis autoimmune – Treatment Malignant fibrous histiocytoma – Trials in Disease Osteosarcoma – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Mucopolysaccharidosis II – Trials in Disease Mantle cell lymphoma stage III – Trials in Disease Cystic fibrosis lung – Life with Disease Lymphatic malformation – Life with Disease Medulloblastoma recurrent Undifferentiated sarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AZD5335 DROSPIRENONE Celecoxib Exemestane RIKKUNSHITO Lixisenatide Pivmecillinam Hydrochloride Amb-05X Belatacept Oms906 Flucloxacillin Zinc Sulphate Heptahydrate Maribavir Macrogol 3350 Clascoterone Lbl-007 Tigecycline Cimetidine Dactinomycin N-Tec More therapies…

    Learn about Your Condition

    Retinal artery occlusion Malignant melanoma stage III Sinusitis bacterial Urinary tract infection Obsessive-compulsive disorder Glioblastoma Schizophreniform disorder Hypochromic anaemia Acarodermatitis Penile squamous cell carcinoma Latent tuberculosis Ependymoma malignant Cardiac amyloidosis Femoral hernia Glaucoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Glomerulonephritis membranous

  • A Study of Povetacicept Compared to Tacrolimus for Adults with Primary Membranous Nephropathy

    Recruiting

    4 1 1
    Investigated Drugs:
    • Povetacicept
    • Tacrolimus
    Czechia Germany Hungary Ireland Italy The Netherlands +1

  • Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    • Nephrotic syndrome
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • Atacicept
    Belgium France Germany Italy Poland Spain

  • Evaluating Dapagliflozin’s Effect on Immune Activity in Patients with Membranous Nephropathy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    Investigated Drugs:
    • Dapagliflozin
    France

  • Study on the Safety and Effects of AP1189 for Patients with Idiopathic Membranous Nephropathy and Severe Proteinuria

    Recruiting

    2 1
    Investigated Drugs:
    • Resomelagon
    Denmark Sweden

  • Study of obinutuzumab to reduce PLA2R antibodies in patients with primary membranous nephropathy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    Investigated Drugs:
    • Obinutuzumab
    The Netherlands

  • Study on the Effectiveness and Safety of Obinutuzumab and Tacrolimus for Patients with Primary Membranous Nephropathy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    Investigated Drugs:
    • Obinutuzumab
    • Tacrolimus
    France Italy Poland Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!